Search for: "In Re: Purdue Pharma L.P." Results 1 - 20 of 38
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Aug 2022, 6:48 pm by Lawrence B. Ebert
Amgen, 580 F.3d at 1365–67; Purdue Pharma L.P. v. [read post]
20 Mar 2020, 2:04 pm by Andrews & Thornton
  She represents her clients as counsel to the Co-Chair of the Official Committee of Unsecured Creditors in Purdue Pharma (In re Purdue Pharma L.P., Bankruptcy No. 19-23649, Chapter 11) She has served to represent victims in eight major bankruptcies. [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
1 Feb 2016, 10:43 am by Lawrence B. Ebert
Plaintiffs-appellantsPurdue Pharma L.P., The P.F. [read post]
3 Sep 2015, 3:06 pm by Lawrence B. Ebert
In re Anthony,414 F.2d 1383 (CCPA 1969) (FDA, not USPTO, is responsible for safety ofdrugs which are sought to be patented); In re Watson, 517 F.2d 465 (CCPA1975) (Congress has given responsibility to FDA, not USPTO, to determinein the first instance whether drugs are safe); Purdue Pharma L.P. v. [read post]
9 Apr 2015, 5:00 am
  This time, we don’t care much about the peculiar facts, but rather we’re directing ourselves to the court’s odd reasoning that somehow there’s a conflict between the learned intermediary rule (adopted at some level now in everyAmerican jurisdiction – see our “headcount” post here − and the Uniform Contribution Among Tortfeasors Act (“UCATA”). [read post]
29 May 2014, 5:00 am
”  Today we’re examining another Louisiana legal peculiarity. [read post]
19 Sep 2013, 9:53 am by Bexis
., 712 F.3d 60 (1st Cir. 2013) – all of which also travel under the heading, In re Neurontin Marketing and Sales Practices Litigation. [read post]
16 Apr 2013, 8:36 pm by Lawrence B. Ebert
Purdue Pharma Prods. [read post]
15 Sep 2011, 5:00 am by Bexis
A reader recently recommended that we take a look at Rounds v. [read post]